Analyst firms · Leerink Partners · LLY
Leerink Partners LLY price target and rating history
Eli Lilly and Company (LLY) · Health Care
Leerink Partners rates Eli Lilly and Company (LLY) Outperform with a $1,104 price target, as of its latest action on Nov 10, 2025. It has published 3 rating actions on LLY since May 2022, including 1 upgrade and 1 downgrade. Across 8 firms with a LLY price target in the last 12 months, the median target is $1,250.
- Current rating
- Outperform
- Price target
- $1,104
- Median target, all firms
- $1,250
- Actions on LLY
- 3
Leerink Partners price target on LLY
Every Leerink Partners rating on LLY
- Nov 10, 2025
- Aug 7, 2025
- May 23, 2022
How other firms rate LLY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Berenberg | Buy | $1,400 | Sep 15, 2026 |
| HSBC | Reduce | $850 | Mar 17, 2026 |
| RBC Capital Markets | Outperform | $1,250 | Feb 25, 2026 |
| Barclays | Overweight | $1,350 | Feb 20, 2026 |
| UBS | Buy | $1,250 | Jan 7, 2026 |
| Daiwa | Buy | $1,230 | Dec 16, 2025 |
| Goldman Sachs | Buy | $1,145 | Dec 15, 2025 |
| BofA Securities | Buy | $1,268 | Dec 15, 2025 |
Questions about Leerink Partners and LLY
- What is Leerink Partners's price target for LLY?
- Leerink Partners's latest stated price target for Eli Lilly and Company (LLY) is $1,104, from its action on Nov 10, 2025.
- What is Leerink Partners's rating on LLY?
- Leerink Partners rates LLY Outperform, a bullish rating, as of Nov 10, 2025.
- When did Leerink Partners last change its view on LLY?
- On Nov 10, 2025, Leerink Partners upgrades to Outperform from Market Perform, price target $1,104.
- How does Leerink Partners's LLY target compare with other analysts?
- Across 8 firms with a LLY price target in the last 12 months, the median target is $1,250.
More LLY rating histories
- Berenberg4
- HSBC4
- Barclays3
- UBS4
- Daiwa4
- BofA Securities4
- BMO Capital Markets3
- Citigroup3
- DZ Bank3
- Morgan Stanley6
- Wells Fargo3
All Leerink Partners ratingsLLY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.